GlassScriptPhysician profile
Fahd Jajeh
NPI 1558355255
$16,278.57
in general payments reported to CMS, 2019-2025
55 companies · $1,974 in 2025
The $1,974 reported for 2025 was more than what 83% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,045 · 2020: $2,244 · 2021: $2,739 · 2022: $2,841 · 2023: $2,451 · 2024: $1,984 · 2025: $1,974.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,409.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,409.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,778.13 | 2019-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $1,477.71 | 2019-2024 | Xarelto, Opsumit |
| Novartis Pharmaceuticals Corporation | $1,223.75 | 2019-2025 | |
| Pfizer INC. | $1,097.20 | 2019-2025 | |
| Amgen INC. | $968.12 | 2019-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $945.33 | 2019-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $920.15 | 2019-2025 | Jardiance |
| Abbott Laboratories | $861.35 | 2019-2025 | Cardiomems, Aveir, Perclose Prostyle |
| Boston Scientific Corporation | $735.58 | 2019-2025 | Watchman Flx, Watchman Access System |
| Astrazeneca Pharmaceuticals LP | $697.75 | 2019-2025 | Wainua, Farxiga, Brilinta |
| Alnylam Pharmaceuticals INC. | $582.73 | 2022-2025 | Onpattro |
| Amarin Pharma, INC. | $559.23 | 2019-2023 | |
| Abiomed | $526.51 | 2019-2025 | Impella |
| Esperion Therapeutics, INC. | $449.48 | 2020-2025 | Nexletol |
| Novo Nordisk INC | $368.42 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fahd Jajeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.